We’ve recently updated our valuation analysis.

Viatris Valuation

Is VTRS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VTRS?

Other financial metrics that can be useful for relative valuation.

VTRS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue2x
Enterprise Value/EBITDA5.7x
PEG Ratio1.1x

Price to Earnings Ratio vs Peers

How does VTRS's PE Ratio compare to its peers?

The above table shows the PE ratio for VTRS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average27.2x
CTLT Catalent
31.6x14.9%US$12.9b
RPRX Royalty Pharma
33.1x64.9%US$23.5b
OGN Organon
7.5x0.9%US$7.6b
ZTS Zoetis
36.5x8.2%US$77.2b
VTRS Viatris
18x16.7%US$14.7b


Price to Earnings Ratio vs Industry

How does VTRS's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.1%
n/an/an/a


Price to Earnings Ratio vs Fair Ratio

What is VTRS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VTRS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio18x
Fair PE Ratio21.8x

Price-To-Earnings vs Fair Ratio: VTRS is good value based on its Price-To-Earnings Ratio (18x) compared to the estimated Fair Price-To-Earnings Ratio (21.8x).


Share Price vs Fair Value

What is the Fair Price of VTRS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VTRS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$11.92
US$13.45
+12.8%
16.9%US$18.00US$10.00n/a12
Feb ’24US$12.26
US$13.45
+9.7%
16.9%US$18.00US$10.00n/a12
Jan ’24US$11.13
US$13.27
+19.3%
18.2%US$18.00US$10.00n/a11
Dec ’23US$11.24
US$13.27
+18.1%
18.2%US$18.00US$10.00n/a11
Nov ’23US$10.25
US$12.55
+22.4%
22.4%US$18.00US$9.00n/a11
Oct ’23US$8.52
US$13.50
+58.5%
27.2%US$21.00US$9.00n/a10
Sep ’23US$9.57
US$13.70
+43.2%
26.9%US$21.00US$9.00n/a10
Aug ’23US$9.66
US$13.90
+43.9%
28.7%US$21.00US$9.00n/a10
Jul ’23US$10.71
US$14.00
+30.7%
28.4%US$21.00US$9.00n/a10
Jun ’23US$12.07
US$14.46
+19.8%
24.7%US$21.00US$10.00n/a12
May ’23US$10.33
US$14.38
+39.2%
25.4%US$21.00US$10.00n/a12
Apr ’23US$10.82
US$14.12
+30.5%
25.7%US$21.00US$10.00n/a13
Mar ’23US$10.15
US$15.96
+57.3%
18.2%US$21.00US$10.00n/a13
Feb ’23US$15.07
US$18.43
+22.3%
15.3%US$24.00US$14.00US$12.2614
Jan ’23US$13.53
US$18.71
+38.3%
15.8%US$24.00US$14.00US$11.1314
Dec ’22US$12.09
US$19.50
+61.3%
15.7%US$25.00US$15.00US$11.2414
Nov ’22US$13.82
US$19.29
+39.5%
15.4%US$25.00US$15.00US$10.2514
Oct ’22US$13.60
US$19.29
+41.8%
15.4%US$25.00US$15.00US$8.5214
Sep ’22US$14.59
US$19.29
+32.2%
15.4%US$25.00US$15.00US$9.5714
Aug ’22US$14.07
US$19.50
+38.6%
15.2%US$25.00US$15.00US$9.6614
Jul ’22US$14.75
US$19.44
+31.8%
16.6%US$26.00US$15.00US$10.7118
Jun ’22US$15.26
US$19.65
+28.7%
16.3%US$26.00US$15.00US$12.0717
May ’22US$13.30
US$19.53
+46.8%
17.3%US$26.00US$15.00US$10.3317
Apr ’22US$13.90
US$19.53
+40.5%
17.3%US$26.00US$15.00US$10.8217
Mar ’22US$14.72
US$20.17
+37.0%
14.3%US$26.00US$15.00US$10.1518
Feb ’22US$17.45
US$22.06
+26.4%
14.3%US$27.00US$17.00US$15.0718


Discover undervalued companies